Loading stock data…
BAX
$20.03+0.79 (+4.11%)
Market ClosedLast close Jun 9
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Baxter International Inc. in the Healthcare sector is trading at $20.03. Wall Street consensus targets $21.54 (12 analysts), implying a +7.5% move over the next 12 months. The stock is currently 37% below its 52-week high of $32.04, remaining 1.2% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +7.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$20.03
Potential Downside
0%
Whystock Fair Value$20.03
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus12 analysts
Hold
Mean target$21.54+7.5%
Range$17.00 – $40.00
Fundamentals
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.95%
ROE
Average efficiency. Growth may require heavy reinvestment.
-18.17%
Volume
Today's trading volume
6.49M
Recent News
FMS and Home Dialysis: How 5008X Could Reset Demand
FMS scales 5008X high-volume HDF and expands home dialysis, aiming for benefits later in 2026 and a bigger payoff in 2027+.
Why Baxter (BAX) Shares Are Sliding Today
Shares of healthcare company Baxter International (NYSE:BAX) fell 1% in the morning session after Citigroup downgraded the stock to Sell from Neutral and lowered its price target to $17.
Has Baxter International (BAX) Overreacted After Recent 10.9% Weekly Share Price Jump
Wondering whether Baxter International at around US$19.18 is a bargain or a value trap? This article walks through what the current price might actually imply. The stock has moved sharply in the short term, with a 10.9% gain over the past week and 5.6% over the past month, despite being down 1.6% year to date and declining 35.5% over the past year and 50.2% over three years. These moves sit against an ongoing evergreen interest in Baxter International as a large healthcare equipment company...
1 Stock Under $50 Worth Investigating and 2 Facing Challenges
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
Baxter Stock Is Testing a Bottom After Healthcare Sector Decimation
Baxter International (BAX) shares are attempting a technical turnaround, breaking a multi-week downtrend that increasingly appears to have bottomed around $16. The stock currently carries an 8% “Sell” technical opinion from Barchart, but that’s down from 88% a week ago and 56% a month ago. Technical indicators show an aggressive...